Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Location
5300 Memorial Drive, Suite 950, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 137 % -65.5%
Debt-to-equity 1.21K % +3510%
Return On Equity -1.68K % -1574%
Return On Assets -128 % -70.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.3M shares +1082%
Common Stock, Shares, Outstanding 30.2M shares +1080%
Entity Public Float 9M USD -43.8%
Common Stock, Value, Issued 30K USD +900%
Weighted Average Number of Shares Outstanding, Basic 15.5M shares +510%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 16.4M USD -10%
General and Administrative Expense 8.9M USD -4.79%
Operating Income (Loss) -25.4M USD +8.24%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -26.6M USD -5.5%
Earnings Per Share, Basic -3 USD/shares +67.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.56M USD -30.3%
Assets, Current 9.08M USD -33.9%
Property, Plant and Equipment, Net 99K USD -55.2%
Operating Lease, Right-of-Use Asset 370K USD -22.1%
Other Assets, Noncurrent 900K USD
Assets 21.6M USD -15.6%
Accounts Payable, Current 3.72M USD +31.3%
Employee-related Liabilities, Current 1.68M USD +44.9%
Accrued Liabilities, Current 4.19M USD +43.9%
Liabilities, Current 7.91M USD +37.7%
Operating Lease, Liability, Noncurrent 292K USD -30.5%
Liabilities 28.8M USD +265%
Retained Earnings (Accumulated Deficit) -167M USD -18.8%
Stockholders' Equity Attributable to Parent -7.17M USD -140%
Liabilities and Equity 21.6M USD -15.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.56M USD +32.1%
Net Cash Provided by (Used in) Financing Activities 8M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 30.2M shares +1080%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.44M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.56M USD -30.3%
Deferred Tax Assets, Valuation Allowance 38.6M USD +19.6%
Deferred Tax Assets, Gross 38.7M USD +19.5%
Operating Lease, Liability 478K USD -16.7%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26.6M USD -5.54%
Lessee, Operating Lease, Liability, to be Paid 566K USD -20.5%
Operating Lease, Liability, Current 128K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 164K USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD +8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 141K USD -14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 61K USD -56.7%
Operating Lease, Payments 157K USD +25.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 123K USD -4.65%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -17.9%
Share-based Payment Arrangement, Expense 1.68M USD -12.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%